Bryostatin-1 for Advanced Renal Cancer
Author Information
Author(s): Madhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P, Turner A, Balkwill F, Hoare S, Harris A L
Primary Institution: Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK
Hypothesis
Can bryostatin-1 improve response rates and reduce toxicity in patients with advanced renal cancer?
Conclusion
Bryostatin-1 was reasonably well tolerated, but did not significantly impact disease progression in renal cancer patients.
Supporting Evidence
- Three patients achieved stable disease lasting for 10.5, 8, and 5.5 months.
- No complete or partial responses were observed.
- Bryostatin-1 was reasonably well tolerated with expected side effects.
Takeaway
This study tested a new drug called bryostatin-1 on patients with kidney cancer, but it didn't help most of them get better.
Methodology
A multicentre phase II trial with patients receiving bryostatin-1 as a continuous infusion for 3 out of 4 weeks.
Potential Biases
Potential bias due to the small number of evaluable patients and lack of control group.
Limitations
No complete or partial responses were observed, and the sample size was small.
Participant Demographics
11 males and 5 females, median age 59 years (range 44–68).
Statistical Information
P-Value
0.03
Statistical Significance
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website